EN DE
Watch Hyundai Pharm for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Hyundai Pharm (004310) fair value: what the stock is really worth

As of Nov 6, 2026: fair value (intrinsic value) of Hyundai Pharm stock KRW 1,621, price KRW 6,120, that is 73.5% below the price, quality 57 out of 100. Rating: strongly overvalued. Calculated from audited financials with 16 of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare KR · ISIN KR7004310009

HP Hyundai Pharm logo Broad data Nov 8, 2026

Hyundai Pharm

004310 · KO
Solid, but very expensive

Our calculation puts a fair price 74% below what the stock costs today.

Low debt
Broad data
Quality 57/100
Mixed Growth (revenue 5y +7.6 %/yr in KRW)
Thin margins · 1.3% net margin (TTM)
0.5% dividend yield · Token dividend
Costs 133 times its yearly profit.
Fair value 1,621 KRW · Strongly overvalued
Negative free cash flow
Trails peers (4/13)
Narrow moat 20/100
Watch Hyundai Pharm for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

14,300 KRW 2,992 KRW Fair Value 1,621 KRW May 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 8, 2026.

How to read this chart

60‑month range 2,992 KRW – 14,300 KRW · fair‑value band 1,210 KRW – 1,963 KRW · the 6,120 KRW price screens above the 1,621 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 2 fiscal years are left out: there the valuation rested on only a fraction of the usual models. As of Nov 8, 2026.

Follow Hyundai Pharm in your weekly email

Every Wednesday you see whether Hyundai Pharm is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Hyundai Pharmaceutical Co., Ltd. manufactures and distributes pharmaceutical products, health food drinks, and medical devices in South Korea and internationally.

Show moreShow less

The company offers a range of ETC and OTC products in various therapeutic areas, including antianginal, antibiotic, antiemetics+antinauseants, antihistamines and antiallergics, antihyperlipidemic, antihypertensive, antiplatelet agent, antitussives, cell stimulants and proliferants, central nervous system, depilatory, dermatological agent, dermatology, dietary supplements, digestive system, endocrine system, expectorants, eye tonic and vitamins, gynaecolog antifungals, gynaecologic antiseptics, hemostatics, labour inhibitors, leukotriene modulator, narcotic analgesics, NSAIDs, oestrogens, ophthalmic products, OTH.sex horm and similar, SERMS, systemic hormonal contraceptives, urogenital system depilatory, uterotonic products, various alimentary tract and metabolism products, vitamins, acne, allergy, alopecia treatment, analgesics and anti-inflammatory, anemia, antimicrobial and antivirus, arthritis, contraceptives, dermatological agent, diagnostic reagent, gastrointestinal disorder and digestant, lip care, nutrition, ophthalmic product, respiratory, urogenital system, wound healing, and others.

Hyundai Pharmaceutical Co., Ltd. was founded in 1965 and is headquartered in Seoul, South Korea.

Stock analysis

Hyundai Pharm (004310) currently trades at 6,120 KRW, while our model-based Fair Value estimate is 1,621 KRW, 74% below the price, so the stock looks overvalued today.

Show more

Valuation

Bull case: the Asset-Based group reads highest at a median of 1,621 KRW per share, and 0 of the 16 models we run sit above the 6,120 KRW price.

Bear case: the Dividend Discount group reads lowest at 285.77 KRW, and 16 of the 16 models stay below the price. Data coverage for this calculation is high.

Scenario range: 1,210 KRW (bear) to 1,963 KRW (bull), the price of 6,120 KRW sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 57/100 (solid quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

Hyundai Pharm reported revenue of 192B KRW in FY2025 versus 140B KRW in FY2021, a compound +8.2%/yr. Reported net income was 2.5B KRW in FY2025.

Key figures

Market cap 189B KRW (≈ $140M) Micro · P/E ratio 133.3 · P/S ratio 1.75 · EPS (TTM) 45.76 KRW · Dividend yield 0.5% · Net margin 1.3% · Return on equity 1.5% · Return on assets (EBIT) 2.1% (5-year average).

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 20 out of 100 (medium confidence).

What moves the price

The share trades about 57% below its 52-week high and 73% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at −74%, 004310 screens richer than that median.

Fair Value models

The price assumes far more growth than our models allow for, so the models scatter widely (228.39 KRW to 3,357 KRW). Read the Fair Value as a cautious anchor, not a price target; the Growth Forecast section shows what the price assumes.
Bear 1,210 KRW Fair Value 1,621 KRW Bull 1,963 KRW
Price 6,120 KRW · Downside -73.5%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 11 months old). Earnings retained since then (14.86 KRW per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
Residual Income 1,617 KRW 1,646 KRW 1,759 KRW 76
EPV 790.17 KRW 901.00 KRW 991.56 KRW 74
ROIC Compounder 790.17 KRW 901.00 KRW 991.56 KRW 72
All 16 models by family
Earnings-Based
Graham-Dodd 553.45 KRW 1,502 KRW 1,969 KRW 65
Lynch FV 295.69 KRW 422.41 KRW 549.13 KRW 61
PEG = 1.0 295.69 KRW 422.41 KRW 549.13 KRW 57
EPV 790.17 KRW 901.00 KRW 991.56 KRW 74
Dividend Discount
Gordon GGM 181.90 KRW 310.38 KRW 408.64 KRW 68
DDM Multi-Stage 181.90 KRW 261.16 KRW 329.98 KRW 67
Multiples
P/E Multiple 1,343 KRW 1,791 KRW 2,238 KRW 63
P/S Multiple 1,038 KRW 1,384 KRW 1,730 KRW 58
P/B Multiple 2,518 KRW 3,357 KRW 4,196 KRW 55
EV/EBIT 194.75 KRW 766.74 KRW 1,339 KRW 59
EV/EBITDA 1,345 KRW 2,301 KRW 3,256 KRW 65
EV/Revenue n/a 228.39 KRW 753.28 KRW 50
Asset-Based
NCAV (Graham) 1,210 KRW 1,621 KRW 2,419 KRW 54
Economic Profit
Residual Income 1,617 KRW 1,646 KRW 1,759 KRW 76
ROIC Compounder 790.17 KRW 901.00 KRW 991.56 KRW 72
Growth Earnings
Growth-Adj P/E 1,057 KRW 1,510 KRW 1,963 KRW 67

Open the full fair value analysis →

Quality Score breakdown

Overall quality 57/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 49
How much profit the company makes from its sales and capital
Quality Growth 62
Are margins and returns getting better?
Cashflow 10
Do the profits arrive as real cash?
Financial strength 53
Debt, balance sheet and risk of trouble
Investment 98
Does it invest with discipline instead of growing at any price?
Low Volatility 43
How calm the share price moves, does not count
Price momentum 54
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 62
Distance to the 52-week high, does not count
New shares 90
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 35/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+9.1%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+5.6%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+7.6%
Start year 2020 (pandemic)
Revenue growth 15 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+3.7%
What shareholders gained per year (last 5 years), in KRW ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in KRW: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+10.2%
Earnings growth per share plus dividend.
Earnings per share, growth per year+9.7%
Dividend (yield on the price)0.5%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.2% → 2%

004310 screens overvalued: fair value 74% below the price. Compare with Merck KGaA →

Compare Hyundai Pharm with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 549 stocks

Beats the industry median on 4/13 measures
Overall it trails its industry peers.
Valuation
Quality Score 57 · Above median
Fair Value upside −73.5% · Bottom 25%
Profitability
Return on equity (12 months) 1.5% · Below median
Return on assets 1.5% · Below median
Net margin (12 months) 1.3% · Below median
Operating margin (12 months) 1.7% · Below median
Growth and dividend
Revenue growth (quarter YoY) 5.0% · Above median
Dividend yield (12 months) 0.5% · Bottom 25%
Balance sheet
Debt / equity 0.07× · Below median

Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper

P/E (12 months) 133.3× · Priciest 25%
P/B 2.30× · Pricier than median
P/S (12 months) 1.75× · Cheaper than median
EV/EBITDA 44.7× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 15
FUTURE (revenue growth)25 · sector 25
PAST (return on equity)6 · sector 29
HEALTH (low debt)97 · sector 96
DIVIDEND (yield)10 · sector 32

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Zoetis Inc ZTS $79.40 $113.53 +43% vs 004310
Jiangsu Hengrui Pharmaceuticals Co 600276 ¥50.43 ¥55.21 +9% vs 004310
Sun Pharmaceutical Industries Limited SUNPHARMA ₹1,860 ₹1,947 +5% vs 004310
Haleon plc HLN $9.14 $8.61 −6% vs 004310
Merck KGaA MRK €148.75 €109.18 −27% vs 004310
Galderma Group GALD CHF 191.75 CHF 109.86 −43% vs 004310
Takeda Pharmaceutical Company TAK $21.02 $11.31 −46% vs 004310
Teva Pharmaceutical Industries Limited TEVA $42.61 $20.74 −51% vs 004310
Sandoz Group SDZ CHF 83.78 CHF 39.70 −53% vs 004310
Divi's Laboratories Limited DIVISLAB ₹10,321 ₹1,567 −85% vs 004310

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Hyundai Pharm: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Hyundai Pharm Fair Value". https://www.fairvalue-calculator.com/stock/004310

Frequently asked questions

Is Hyundai Pharm (004310) overvalued or undervalued?
As of Nov 8, 2026, our model estimates a fair value of 1,621 KRW versus a price of 6,120 KRW, about 74% lower (overvalued).
What is the fair value of 004310?
Our model-based fair value for Hyundai Pharm is 1,621 KRW (as of Nov 8, 2026), built from audited fundamentals. The current price: 6,120 KRW.
What is the quality score of 004310?
Hyundai Pharm has a Quality Score of 57/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Hyundai Pharm (004310)?
Our model-based price target is the fair value of 1,621 KRW (as of Nov 8, 2026) from 16 valuation models. Cautious scenario 1,210 KRW, optimistic scenario 1,963 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the Hyundai Pharm stock forecast for 2026?
Our models put fair value at 1,621 KRW, about 74% lower versus a price of 6,120 KRW (overvalued). Cautious scenario 1,210 KRW, optimistic scenario 1,963 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of Hyundai Pharm (004310)?
Hyundai Pharm reported trailing-twelve-month revenue of about 108B KRW (latest available figure, as of Nov 8, 2026).
Does Hyundai Pharm pay a dividend?
Hyundai Pharm currently shows a dividend yield of 0.49% relative to its recent price (as of Nov 8, 2026).
How much is the dividend of Hyundai Pharm (004310) and when is the ex-dividend date?
Hyundai Pharm pays a dividend of 30.00 KRW per share a year, a dividend yield of 0.5%. The last ex-dividend date was Mar 3, 2026. The payout ratio is 65.6% of earnings. Our assessment: Token dividend. At a yield of 0.5% the dividend is symbolic. On paper it is not fully covered by earnings or free cash flow, but at this size that hardly matters: even scrapping it entirely would cost less than 0.5% a year, and coverage ratios on amounts this small swing with ordinary working-capital movements. Judge this company on its business, not on its dividend.
What is the intrinsic value of Hyundai Pharm (004310)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Hyundai Pharm it is 1,621 KRW per share (as of Nov 8, 2026), against a price of 6,120 KRW. It is the blended result of 16 valuation models in 6 families (Earnings-Based, Dividend Discount, Multiples, Asset-Based, Economic Profit, Growth Earnings).
Is Hyundai Pharm stock overvalued or undervalued in 2026?
As of Nov 8, 2026, 004310 trades above its calculated fair value: price 6,120 KRW, fair value 1,621 KRW, a gap of about −74% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 004310?
No. The price is what the market pays today (6,120 KRW); the fair value is what the company's own numbers justify (1,621 KRW). For Hyundai Pharm the two are 4,499 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is Hyundai Pharm worth?
The market values Hyundai Pharm at about 189B KRW (market capitalisation, as of Nov 8, 2026). Per share that is 6,120 KRW; our models calculate a fair value of 1,621 KRW per share.
What do the bullish and bearish scenarios say about 004310?
Our models span a range for Hyundai Pharm: cautious scenario 1,210 KRW, base 1,621 KRW, optimistic 1,963 KRW per share (as of Nov 8, 2026, price 6,120 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 004310?
Hyundai Pharm trades at a price-to-earnings ratio of 133.3 (as of Nov 8, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 1,621 KRW is built from several models across several years. Median P/E at fiscal year-end, 7 fiscal years (2013 to 2025), reported earnings: 60.8. Other multiples: P/B 2.3, P/S 1.7, EV/EBITDA 44.7.
How solid is the balance sheet of Hyundai Pharm (004310)?
Balance-sheet figures for Hyundai Pharm (as of Nov 8, 2026): return on equity 1.5%, debt of 0.07 per unit of equity. They feed the Quality Score of 57/100, which measures business quality independently of the share price.
How far is 004310 from its 52-week high?
Hyundai Pharm trades at 6,120 KRW, about 57% below its 52-week high of 14,300 KRW and 73% above the low of 3,535 KRW (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of 1,621 KRW is for.
Which stocks are comparable to Hyundai Pharm?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Galderma Group, Teva Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Hyundai Pharm stock attractive at the current price?
The data as of Nov 8, 2026: price 6,120 KRW, calculated fair value 1,621 KRW (−74%), Quality Score 57/100, from 16 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 004310 calculated?
We run Hyundai Pharm through 16 models from 6 families: Earnings-Based, Dividend Discount, Multiples, Asset-Based, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of 1,621 KRW builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Hyundai Pharm itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Hyundai Pharm (004310)?
The closing price on Nov 6, 2026 was 6,120 KRW. Our model-based fair value is 1,621 KRW, about 74% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Hyundai Pharm right now?
The price sits above even our optimistic bull case (1,963 KRW). The favourable scenario is already priced in. Solid but not exceptional quality (57/100) and above fair value, neither a clear bargain nor a standout compounder.

Key figures of Hyundai Pharm

How large is the market capitalisation of Hyundai Pharm (004310)?
The market capitalisation of Hyundai Pharm is 189B KRW (≈ $140M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Hyundai Pharm (004310)?
The price-to-sales ratio of Hyundai Pharm is 1.75 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Hyundai Pharm (004310)?
Earnings per share at Hyundai Pharm are 45.76 KRW (price ÷ EPS = P/E 133.3). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Hyundai Pharm (004310)?
The dividend yield of Hyundai Pharm is 0.5% (payout 65.6%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Hyundai Pharm (004310)?
The net margin of Hyundai Pharm is 1.3% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Hyundai Pharm (004310)?
The return on equity (ROE) of Hyundai Pharm is 1.5% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Hyundai Pharm (004310)?
On an EBIT basis the return on assets of Hyundai Pharm is 2.1% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Hyundai Pharm (004310)?
The operating margin of Hyundai Pharm is 1.7% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Hyundai Pharm (004310)?
Revenue at Hyundai Pharm is growing +5.0% versus a year earlier (3y avg +5.6%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Hyundai Pharm (004310) generate?
The free cash flow of Hyundai Pharm is −6.0B KRW (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Hyundai Pharm (004310) carry?
The net debt of Hyundai Pharm is 47.0B KRW (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Hyundai Pharm in the live analysis

One click puts Hyundai Pharm on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.